Latest Raya Therapeutic News & Updates

See the latest news and media coverage for Raya. We track all announcements, press releases, and industry mentions in real time, all in one place.

Raya Therapeutic (Raya)

Biotechnology company developing ALS treatments

Last updated Today

Latest news about Raya Therapeutic (Raya)

In short: Raya advanced its neurodegenerative disease pipeline by securing clinical trial placements and multiple orphan drug designations.

March 9 Raya

Raya Therapeutic announces RT1999 selection for EXPERTS-ALS trial

RT1999 (smilagenin) will dose first ALS patient by end of 2026. It received Orphan Drug Designations and shows preclinical neuroprotective activity.
4 December 2025 Raya

Raya Therapeutic unveils Raya CARES pipeline

The pipeline features five clinical-stage compounds with unique mechanisms targeting ALS, PD, and neurodegenerative diseases. Each has established safety data. Raya plans Phase 2/3 trials within 12-18 months.
14 November 2025 Raya

Raya congratulates Alzheimer's Drug Discovery Foundation

Raya highlights its pipeline of 5 pleiotropic NCEs for combination therapies in AD, PD, ALS, and FTD, with a planned ALS trial in 2027.
2 September 2025 Raya

Raya announces compound selection for EXPERTS-ALS trial

One of five clinical-stage compounds advances toward ALS approval in University of Sheffield-led platform trial. Positive data could lead to registration trial.

March 19 Ithaca Journal

Raya Therapeutic Announces Selection of RT1999 (Smilagenin) onto the EXPERTS-ALS Clinical Trial Platform

Positive data from EXPERTS-ALS could accelerate RT1999 towards a registration trial; RT1999 to be presented as a poster at the MDA Conference MONTREAL, QUEBEC, CANADA...
March 9 ALS News Today

MDA 2026: New ALS platform trial adds RT1999 to speed search for treatments

Experimental therapy RT1999 will soon be tested in the UK EXPERTS-ALS platform trial designed to rapidly screen potential ALS treatments.
2 September 2025 KELO

Raya Therapeutic Announces Selection of one of its 5 compounds onto the EXPERTS-ALS Clinical Platform Trial

Positive data from this clinical study could lead to a registration trial of the compound for the treatment of ALS/MND. MONTREAL, QUEBEC, CANADA, September 2...
3 March 2025 FOX40

Raya Therapeutic Announces FDA and EMA Orphan Drug Designations for ALS with RT1978 (epertinib)

The orphan drug designations (ODDs) are from both the FDA & EMA and for the treatment of Amyotrophic Lateral Sclerosis (ALS). MONTREAL, QUEBEC, CANADA, March...

Never miss news about Raya

Track Raya and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Browse news for competitors to Raya and other trending companies.